A low plasma 1,25(OH)(2) vitamin D/PTH (1-84) ratio predicts worsening of renal function in patients with chronic heart failure

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

Dysregulation of the vitamin D system promotes renal dysfunction and has direct detrimental effects on the heart.

The researchers examined the relation between two plasma markers of vitamin D metabolism and worsening of renal function (WRF) in a large cohort of patients with chronic HF.

Who Took Part

The abstract describes 1237 patients taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Plasma levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) and parathyroid hormone PTH (1-84) were measured in 1237 patients with clinical evidence of chronic and stable HF enrolled in the multicentre GISSI-HF trial and followed for 3.9years.

How the Study Was Run

The researchers set it up as a randomized, double-blind and multicenter study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.

More than one site took part, so the patients came from several places.

What Was Measured

The subject headings attached to it are Biomarkers, Chronic Disease, Cohort Studies, Heart Failure, Kidney Diseases, Kidney Function Tests and Mortality.

Author keywords: 1,25-dihydroxyvitamin D, Parathyroid hormone and Worsening renal function.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Parathyroid Hormone (PTH 1-84) in 1237 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (International journal of cardiology), a journal based in Netherlands.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.